Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-way Cross-over, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess Pharmacologic Effects of a 7-day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older

NCT00703703 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00703703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00703703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-way Cross-over, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess Pharmacologic Effects of a 7-day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2008
Completion date
October 31, 2008
Enrollment
117 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

healthy